LEADER 01416nam  2200397Ia 450 
001 9910696944203321
005 20230902161730.0
035   $a(CKB)5470000002383451
035   $a(OCoLC)551744655
035   $a(EXLCZ)995470000002383451
100   $a20100312d2003      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for indusry$b[electronic resource] $ebioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2003]
215   $a1 electronic resource (36 pages)
300   $a'Biopharmaceutics."
300   $a"April 2003."
320   $aIncludes bibliographical references (page 34).
517   $aGuidance for indusry 
606   $aAerosols$xBioavailability
606   $aAerosol therapy$zUnited States
606   $aDrugs$zUnited States$xTherapeutic equivalency
615  0$aAerosols$xBioavailability.
615  0$aAerosol therapy
615  0$aDrugs$xTherapeutic equivalency.
712 02$aCenter for Drug Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910696944203321
996   $aGuidance for indusry$93467946
997   $aUNINA